Erratum : Late-Onset Immune Checkpoint Inhibitor-Associated Nephrotoxicity and Suspected Thrombotic Microangiopathy Following Durvalumab Administration with a Challenging Clinical Course: A Case Report | Synapse
February 26, 2026
Erratum : Late-Onset Immune Checkpoint Inhibitor-Associated Nephrotoxicity and Suspected Thrombotic Microangiopathy Following Durvalumab Administration with a Challenging Clinical Course: A Case Report
Key Points
To report a case of late-onset nephrotoxicity and suspected thrombotic microangiopathy following Durvalumab treatment.
Detailed case report of clinical observations and interventions.
Assessment of patient symptoms and treatments post-Durvalumab administration.
Monitoring patient response to therapies and medical interventions.
Identified nephrotoxicity linked to immune checkpoint inhibitor therapy.
Documented suspected thrombotic microangiopathy in the patient.